Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Stanford University30 enrolled

Overview

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetic Nephropathy

Interventions

Addition of furosemide 20 mg oral bid to baseline regimenDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: proteinuria greater than 1 gram/day serum creatinine \< 2.6 for men, \< 2.0 for women Exclusion Criteria: blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months

Locations (2)

Kaiser Permanente of Northern California, Santa Clara and San Jose

Santa Clara, California, United States

Stanford University Medical Center

Stanford, California, United States

Outcomes

Primary Outcomes

The amount of protein in the urine after 8 weeks of treatment.

Secondary Outcomes

The estimated glomerular filtration rate after 8 weeks of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.